UBS Group
STLN

UBS Group’s Starling Oncology STLN Stock Holding History

UBS Group’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$832K Sell
153,273
-421,379
-73% -$1.77M ﹤0.01% 5879
2026
Q1 		$1.76M Buy
574,652
+286,966
+100% +$880K ﹤0.01% 5089
2025
Q4 		$1.02M Sell
287,686
-768,176
-73% -$2.85M ﹤0.01% 5554
2025
Q3 		$3.68M Buy
1,055,862
+635,489
+151% +$2.18M ﹤0.01% 4352
2025
Q2 		$862K Buy
420,373
+410,296
+4,072% +$1.03M ﹤0.01% 5573
2025
Q1 		$11.5K Sell
10,077
-51,884
-84% -$40.2K ﹤0.01% 8549
2024
Q4 		$19.1K Buy
+61,961
New +$16.1K ﹤0.01% 7902
2024
Q2 		– Sell
-10,326
Closed -$16.3K – 10090
2024
Q1 		$16.3K Buy
+10,326
New +$19.6K ﹤0.01% 7010
2023
Q3 		– Sell
-2,414
Closed -$1.33K – 9967
2023
Q2 		$1.33K Sell
2,414
-9,124
-79% -$4.83K ﹤0.01% 7944
2023
Q1 		$7.82K Buy
11,538
+5,377
+87% +$6.86K ﹤0.01% 7775
2022
Q4 		$10.2K Buy
6,161
+4,577
+289% +$12.8K ﹤0.01% 8563
2022
Q3 		$7K Buy
1,584
+1,071
+209% +$6.3K ﹤0.01% 8906
2022
Q2 		$3K Buy
+513
New +$3.74K ﹤0.01% 9367
2022
Q1 		– Sell
-1,859
Closed -$18K – 10905
2021
Q4 		$18K Sell
1,859
-28,584
-94% -$254K ﹤0.01% 7992
2021
Q3 		$303K Buy
30,443
+29,554
+3,324% +$293K ﹤0.01% 5036
2021
Q2 		$9K Buy
+889
New +$8.95K ﹤0.01% 8160
2021
Q1 		– Sell
-502
Closed -$5K – 9469
2020
Q4 		$5K Sell
502
-1,044
-68% -$10.7K ﹤0.01% 7847
2020
Q3 		$16K Buy
+1,546
New +$16.1K ﹤0.01% 6484

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group's STLN Position: Q2 2026 in Review

UBS Group reduced its Starling Oncology (STLN) stake by 73% in Q2 2026, selling an estimated $1.77M and leaving 153,273 shares worth $832K. The position accounts for ﹤0.01% of the portfolio, ranked #5879.

UBS Group first reported a position in STLN in Q3 2020 and has held it in 18 quarters since. The position peaked at $3.68M in Q3 2025. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • UBS Group held 153,273 shares of Starling Oncology worth $832K as of Q2 2026.
  • UBS Group sold 421,379 Starling Oncology shares in Q2 2026, an estimated $1.77M.
  • Starling Oncology made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5879 holding.
  • UBS Group first reported a position in Starling Oncology in Q3 2020 and has held it in 18 quarters since.
  • UBS Group's Starling Oncology position peaked at $3.68M in Q3 2025.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.